Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Adult Ependymoma: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Adult Ependymoma: 1 US clinical trial tracked, none currently recruiting.

Adult Ependymoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 1 of these trials.

Enrollment posture brief

Registry condition adult-ependymoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Adult Ependymoma (this)0%
Open-enrollment share among volume-matched conditions near Adult Ependymoma

Adult Ependymoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adult Ependymoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adult Ependymoma is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Adult Ependymoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gamma-Secretase Inhibitor RO4929097 Drug
1 trials
Pharmacological Study Other
1 trials
3-Dimensional Conformal Radiation Therapy Radiation
1 trials
Intensity-Modulated Radiation Therapy Radiation
1 trials
Laboratory Biomarker Analysis Other
1 trials

US sites by state

Facility locations filed on Adult Ependymoma trials. A trial with sites in several states counts in each.

Virginia 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adult Ependymoma page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult Ependymoma condition card totals 1 registered trials; most-linked intervention Gamma-Secretase Inhibitor RO4929097; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.